Skip to main content

Table 1 Clinical characteristics of all patients and stratified by D5 peripheral blast clearance rate (D5-PBCR)

From: Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia

Characteristics All patients ( n = 96) a D5-PBCR ≥99.55% ( n = 37) D5-PBCR <99.55% ( n = 57) P value
Age, y, median (range) 44.5 (14–74) 44 (15–67) 45 (14–74) 0.467
Gender (no.) 0.996
 Male 61 24 37  
 Female 35 13 20  
WBC count (×109/L), median (range) 13.3 (1.32–249.90) 26.99 (3.2–120.9) 9.20 (1.32–249.90) 0.160
Hemoglobin (g/L), median (range) 85.0 (34.90–136.00) 89.5 (55.0–136.0) 82.0 (34.9–125.0) 0.051
Platelet (×109/L), median (range) 38.0 (3.00–455.00) 38.5 (6.0–179.0) 36.0 (3.0–221.0) 0.975
Blasts in bone marrow (%), median (range) 65.0 (14.50–98.00) 71.0 (21.5–96) 60.1 (14.5–98.0) 0.038
Blasts in peripheral blood (/μL), median (range) 3730.7 (11.32–246,000) 4961.7 (479.9–124,900) 3730.7 (11.32–246,000) 0.035
FAB subtypes (no.) 0.229
 M1 2 1 1  
 M2 24 5 18  
 M4 43 19 24  
 M4Eo 2 2 0  
 M5 19 7 11  
 M6 1 1 0  
 NA 5 2 3  
Cytogenetic-molecular risk group (no.) 0.045
 Favorable 23 12 11 0.148
 Intermediate 53 22 30 0.515
 Unfavorable 20 3 16 0.019
LAIP (no.) -
Cross-lineage antigen expression 63 29 34  
Asynchronous antigen expression 6 0 6  
Antigen dim/strong expression 13 6 6  
Antigen expression missing 8 4 3  
CR (%) 67 (69.79) 35 (94.6) 32 (56.1) <0.001
MRD (+) (%)b 29 (55.77) 14 (50) 15 (62.5) 0.366
Relapse (%) 26 (32.50) 7 (19.44) 18 (42.86) 0.027
  1. NA not available, CR achieved complete remission after one course of induction therapy, LAIP leukemia-associated aberrant immunophenotype, FAB French-American-British, MRD minimal residual disease. aTwo patients lacking in the peripheral blast absolute counts data of day 5 could not be further stratified into different groups according to D5-PBCR; bMRD (+): In 67 patients achieved CR, LAIPs were detectable in 52 cases.